P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study by Barouch DH, Goudsmit J, McElrath MJ, Hural J, LaPorte A, Dilan R, Riggs AM, King SL, Maxfield LF

P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials by Stevens G, Rodriguez-Chavez IR, Needham L, Ozaki D, Hural J, Denny T, Cleland N, Cox J, Sarzotti-Kelsoe M, Stiles T, Tarragona-Fiol T, Simkins A

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting by Spearman P, Tomaras G, Montefiori D, Huang Y, Ahmed H, Elizaga M, Hural J, McElrath J, Ouedraogo L, Pensiero M, Butler C, Kalams S, Overton ET, Barnett S, Group N

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles by Goepfert P, Elizaga M, Montefiori D, Hural J, DeRosa S, Tomaras G, Seaton K, Sato A, Ouedraogo L, Donastorg Y, Cardinali M, Lama J, Baden L, Keefer M, McElrath J, Kalams S, Robinson H

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial by Self SG, Li F, Corey L, Shiver J, Michael NL, Frahm N, Dubey S, Hural J, Raugi DN, Zhao H, Wong K, Deng W, Crossler J, O'Sullivan A, Bradfield A, Bose M, Magaret CC, deCamp AC, Heath L, Sanders-Buell E, Gilbert PB, Tovanabutra S, Rolland M, Kim J, Buchbinder S, Casimiro DR, Robertson MN, McElrath MJ, McCutchan FE, Mullins JI